Page last updated: 2024-09-03

mozavaptan and Polycystic Kidney Diseases

mozavaptan has been researched along with Polycystic Kidney Diseases in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (75.00)29.6817
2010's1 (25.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Baeßler, B; Benzing, T; Borgal, L; Dafinger, C; Franke, M; Göbel, H; Höhne, M; Koerber, F; Maintz, D; Persigehl, T; Schermer, B; Vechtel, J1
Gattone, VH; Harris, PC; Torres, VE; Wang, X1
Doggrell, SA1
Gattone, V; Harris, PC; Torres, VE; Wang, X1

Reviews

1 review(s) available for mozavaptan and Polycystic Kidney Diseases

ArticleYear
Do vasopressin receptor type 2 antagonists have therapeutic potential in polycystic kidney diseases?
    Expert opinion on investigational drugs, 2004, Volume: 13, Issue:4

    Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Drug Evaluation, Preclinical; Humans; Polycystic Kidney Diseases

2004

Other Studies

3 other study(ies) available for mozavaptan and Polycystic Kidney Diseases

ArticleYear
Magnetic resonance T2 mapping and diffusion-weighted imaging for early detection of cystogenesis and response to therapy in a mouse model of polycystic kidney disease.
    Kidney international, 2017, Volume: 92, Issue:6

    Topics: Adult; Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cysts; Diffusion Magnetic Resonance Imaging; Disease Models, Animal; Early Diagnosis; Female; Humans; Image Processing, Computer-Assisted; Kidney; Longitudinal Studies; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Molecular Targeted Therapy; Mutation; NIMA-Related Kinases; Polycystic Kidney Diseases; Proof of Concept Study; Time Factors; Treatment Outcome; Young Adult

2017
Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist.
    Nature medicine, 2003, Volume: 9, Issue:10

    Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Aquaporin 6; Aquaporins; Benzazepines; Cyclic AMP; Disease Models, Animal; Disease Progression; Humans; Kidney; Mice; Polycystic Kidney Diseases; Proteins; Rats; Rats, Sprague-Dawley; Receptors, Vasopressin; TRPP Cation Channels

2003
Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat.
    Journal of the American Society of Nephrology : JASN, 2005, Volume: 16, Issue:4

    Topics: Adenine; Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cyclic AMP; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Female; Guanosine Triphosphate; Introns; Kidney; Male; Phosphorylation; Polycystic Kidney Diseases; Polycystic Kidney, Autosomal Recessive; Proto-Oncogene Proteins B-raf; ras Proteins; Rats; Rats, Sprague-Dawley; Receptors, Cell Surface; Thymine; Tolvaptan

2005